Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 16099976

Refocusing disaster aid.

Joanne Linnerooth-Bayer·Reinhard Mechler·Georg Pflug
View original source ↗Export metadata ↓

Abstract

With new modeling techniques for estimating and pricing the risks of natural disasters, the donor community is now in a position to help the poor cope with the economic repercussions of disasters by assisting before they happen. Such assistance is possible with the advent of novel insurance instruments for transferring catastrophe risks to the global financial markets. Donor-supported risk-transfer programs not only would leverage limited disaster-aid budgets but also would free recipient countries from depending on the vagaries of postdisaster assistance. Both donors and recipients stand to gain, especially because the instruments can be closely coupled with preventive measures.

Explore related subjects

Developed CountriesDeveloping CountriesDisastersFinancing, GovernmentInsuranceInternational CooperationModels, StatisticalProgram DevelopmentRiskRisk Sharing, FinancialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Joanne Linnerooth-Bayer, Reinhard Mechler, Georg Pflug. 2005-08-12. Refocusing disaster aid.. https://doi.org/10.1126/science.1116783

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

[Systematic review of near miss maternal morbidity].

This systematic literature review on maternal near miss aims to evaluate data on the incidence and different operational definitions of near miss. An electronic search was performed in databases of scientific journals and also in the references of the identified studies. Initially, 1,247 studies were identified, 35 of which were comprehensively assessed, with 17 excluded and 18 included. Review of reference lists from these articles identified an additional 20 articles, thus completing 38 studies included: 20 adopting definitions of near miss related to management complexity, 6 to organ dysfunction, 2 with a mixed definition, and 10 according to symptoms, signs, or specific clinical entities. The mean near miss ratio was 8.2/1,000 live births, the maternal mortality index was 6.3%, and the case/fatality ratio was 16:1. The study concluded that there was a trend towards higher incidence of near miss in developing countries and when using near miss definitions by organ dysfunction. The study of near miss maternal morbidity can help improve obstetric care and support the struggle against maternal mortality.

Developed Countries↗
PubMed2006

Proteomics of the heart: unraveling disease.

Heart diseases resulting in heart failure are among the leading causes of morbidity and mortality in developed countries. Underlying molecular causes of cardiac dysfunction in most heart diseases are still largely unknown but are expected to result from causal alterations in gene and protein expression. Proteomic technology now allows us to examine global alterations in protein expression in the diseased heart and can provide new insights into cellular mechanisms involved in cardiac dysfunction. The majority of proteomic investigations still use 2D gel electrophoresis (2-DE) with immobilized pH gradients to separate the proteins in a sample and combine this with mass spectrometry (MS) technologies to identify proteins. In spite of the development of novel gel-free technologies, 2-DE remains the only technique that can be routinely applied to parallel quantitative expression profiling of large sets of complex protein mixtures such as whole cell lysates. It can resolve >5000 proteins simultaneously (approximately 2000 proteins routinely) and can detect <1 ng of protein per spot. Furthermore, 2-DE delivers a map of intact proteins, which reflects changes in protein expression level, isoforms, or post-translational modifications. The use of proteomics to investigate heart disease should result in the generation of new diagnostic and therapeutic markers. In this article, we review the current status of proteomic technologies, describing the 2-DE proteomics workflow, with an overview of protein identification by MS and how these technologies are being applied to studies of human heart disease.

Developed Countries↗